HIV-associated facial lipoatrophy.
BACKGROUND
HIV-infected individuals are living long, healthy lives. They are now concerned with less life-threatening problems, especially lipodystrophy.


OBJECTIVE
To review the current state of our knowledge about lipodystrophy in HIV-infected individuals.


METHODS
The literature was reviewed and analyzed for relevant information. In addition, our clinical experience of managing such individuals was utilized.


RESULTS
Lipodystrophy and facial lipoatrophy and their relationship to HIV-infection are discussed. Their differences are noted. The spectrum of appearance in individuals with facial lipoatrophy is described and a severity scale suggested which should be of value in assessing the results of treatment.


CONCLUSIONS
Lipodystrophy and lipoatrophy are intimately related to infection with HIV. In consequence, facial lipoatrophy is a major stigma for HIV-infected individuals and can have dramatic effects on their self-esteem and socialization. Effective treatment is essential.
James
Julia
J
Division of Dermatology and Department of Ophthalmology, University of British Columbia, Vancouver,British Columbia, Canada.
Carruthers
Alastair
A
Carruthers
Jean
J
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D005145:Face; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000209:etiology / Q000628:therapy*; D006801:Humans; D015187:Lipectomy; D012307:Risk Factors
D017320:HIV Protease Inhibitors